Application of gabapentinoids and novel compounds for the treatment of benzodiazepine dependence: the glutamatergic model.

Halford WarlickLexie LeonRudresh PatelStefanie FiloramoRyan KnipeErnesto JoubranArkene LevyHoang NguyenJose Rey

Published in: Molecular biology reports (2022)

GBPs may benefit individuals undergoing BZD withdrawal, given that the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor current significantly increases during abrupt BZD withdrawal in animal studies. This may be a conceivable explanation for the effectiveness of GBPs in treating both alcohol withdrawal symptoms and BZD withdrawal symptoms in some recent studies. Finally, natural and synthetic GABAergic compounds with unique pharmacodynamic properties were found to exert potential clinical benefits as BZD substitutes in animal studies, though human studies are lacking.

Keyphrases

case control
randomized controlled trial
endothelial cells
systematic review
sleep quality
physical activity
climate change
combination therapy
smoking cessation
replacement therapy